Cardiovascular risk stratification in asymptomatic individuals in Bitola, North Macedonia by using High sensitive Troponin I Assay

• Biljana Ilkovska ^[1] ; Bisera Kotevska Trifunova ^[2] ; Petar Avramovski ^[3]
  1. [1] PHO Clinical Hospital Dr. Trifun Panovski, Department of Laboratory Medicine, Bitola, North Macedonia
  2. [2] dzibadem City Clinic YMBAL Tokuda, Department of dematovenerology, Sofia, Bulgaria
  3. [3] PHO Clinical Hospital Dr. Trifun Panovski, Department of Internal Medicine, Bitola, North Macedonia

  Mostrar afiliaciones +
• Localización: Academic Journal of Health Sciences: Medicina Balear, ISSN-e 2255-0560, Vol. 38, Nº. 2, 2023, págs. 104-109
• Idioma: inglés
• DOI: 10.3306/AJHS.2023.38.02.104
• Títulos paralelos:
  • Estratificación del riesgo cardiovascular en individuos asintomáticos de Bitola, Macedonia del Norte, mediante el uso de la prueba de troponina I de alta sensibilidad
• Enlaces
  • Texto completo (pdf)
• Resumen
  • español

    Objetivos: El objetivo de nuestro estudio de cohorte prospectivo en Macedonia fue evaluar la distribución de las concentraciones de hs-cTnI en individuos sanos para estratificar el riesgo cardiovascular.

    Antecedentes: Las últimas generaciones de hs-cTnI podrían utilizarse para la estratificación del riesgo cardiovascular en la población general, utilizando valores dentro del rango normal.

    Métodos: El estudio se realizó durante un período de un año en 2021. Se midieron las concentraciones de hs-cTnI en 1201 participantes, 690 hombres y 511 mujeres, utilizando el analizador Abbott Architect.

    Resultados: Encontramos que el riesgo elevado de eventos cardiovasculares es mayor en los hombres en comparación con las mujeres, también confirmamos que el riesgo de eventos cardiovasculares aumenta significativamente con la edad en ambos sexos, pero es predominante en los hombres.

    Conclusión: El ensayo hs-cTnI proporciona la detección de troponina en una proporción significativa de individuos asintomáticos.

    La Hs-cTnI permite actuar de forma preventiva en los pacientes con riesgo aumentado incluyendo el tratamiento con estatinas, la regulación del peso o los cambios en el estilo de vida, intensificando la actividad física, mientras que sus valores son paralelos a la modificación del riesgo cardiovascular. Se debe informar a los pacientes que existe la posibilidad de evaluar el riesgo cardiovascular y realizar un examen más masivo de hs-cTnI.

  • English

    Objectives: The aim of our prospective cohort study in Macedonia was to evaluate the distribution of hs-cTnI concentrations in health individuals to stratified cardiovascular risk.

    Background: The latest generations of hs-cTnI could be used for the stratification of cardiovascular risk in the general population, using values within the normal range.

    Methods: Study was performed from one year period in 2021 year. We measured hs-cTnI concentrations in 1201 participants 690 males and 511 females by using Abbott Architect analyzer.

    Results: We found that elevated risk for cardiovascular event is higher in males compared to females, also we confirm that risk of cardiovascular events increase significantly with age in both sexes, but is predominant in males.

    Conclusion: The hs-cTnI assay provides detection of troponin in a significant proportion of asymptomatic individuals. Hs-cTnI allows us to act preventively in patients at increased risk by including statin therapy, weight regulation or lifestyle changes, intensifying physical activity, while its values are parallel to the modification of cardiovascular risk. Patients should be informed that there is a possibility of cardiovascular risk assessment and more massive hs-cTnI examination.

• Referencias bibliográficas
  • World Heart Organization fact sheets: Cardiovascular disease. https://www.who. int/en/news-room/fact-sheets/detail/cardiovasculardiseases-(cvds)...
  • Benjamin EJ, Muntner P, Alonso A, Bittencourt M, Callaway C, Carson A et al. On behalf of the American Heart Association Council on Epidemiology...
  • Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano A et al. European Guidelines on cardiovascular disease prevention in clinical practice....
  • Conroy R, Pyorala K, Fitzgerald Ae , Sans S, Menotti A, Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the...
  • Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino R, Gibbons R et al. 2013 ACC/AHA guideline on the assessment of cardiovascular...
  • Amsterdam EA , Wenger NK, Brindis RG, Casey Jr D, Ganiats T, Holmes D et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation...
  • Apple FS , Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population....
  • Sinning C , Keller T, Zeller T, Schlüter M, Schnabel R, Lubos E et al. Association of high-sensitivity assayed troponin I with cardiovascular phenotypes...
  • de Lemos JA , Drazner MH, Omland T, Ayers C, Khera A, Rohatgi A et al. Association of troponin T detected with a highly sensitive assay and...
  • Omland T , de Lemos JA, Holmen OL, Dalen H, Benth JS, Nygard S et al. Impact of sex on the prognostic value of high-sensitivity cardiac troponin...
  • Zeller T , Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel R, Tuovinen T et al. High population prevalence of cardiac troponin I measured by...
  • Thygesen K, Alpert JS, Jaffe AS et al. ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart...
  • Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreeotti F et al. ESC Guidelines for the management of acute coronary syndromes...
  • Kvisvik B, Mørkrid L, Røsjø H, Cvancarova M, Rowe AD, Eek C et al. Prognosis in ACS high-sensitivity troponin T vs I inacute coronary syndrome:...
  • McCarthy CP, McEvoy JW, Januzzi JL Jr. Biomarkers in stable coronary artery disease. Am Heart J 2018; 196: 82-96.
  • Daubert MA, Jeremias A. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk...
  • Casas JP, Shah T, Hingorani AD, Danesh J, Pepys MB. C-reactive protein and coronary heart disease: a critical review. J Intern Med 2008; 264:...
  • D’Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al. General cardiovascular risk profile for use in primary care:...
  • Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, Backer G et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular...
  • Woodward M, Brindle P, Tunstall-Pedoe H. SIGN group on risk estimation. Adding social deprivation and family history to cardiovascular risk...
  • Stone NJ, Robinson JG, Lichtenstein AH, Merz CN, Blum C, Eckel R et al. American College of Cardiology/American Heart Association Task Force...
  • Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini G, McPherson R et al. 2012 update of the Canadian Cardiovascular Society guidelines...
  • Farmakis D, Andreadou I, Aessopos A. High-sensitivity troponin assays: ready for prime-time use as surrogates of subclinical myocardial injury?...
  • Ibanez B, James S, Agewall S, Antunes M, Ducci C, Bueno H et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of...
  • Wu AHB, Christenson RH, Greene DN, Jaffe A, Kavsak P, Llanos JO et al. Clinical laboratory practice recommendations for the use of cardiac troponin...
  • Collinson PO, Saenger AK, Apple FS; on behalf of the IFCC C-CB. High sensitivity, contemporary, and point-of-care cardiac troponin assays:...
  • Apple FS, Collinson PO. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem 2012; 58: 54-61.
  • Architect STAT High Sensitive Troponin-I [package insert]. Lake Bluff, IL: Abbott Laboratories 2018. G97079R01.
  • Alinity i STAT Troponin-I [package insert]. Lake Bluff, IL: Abbott Laboratories; 2019. H05938R01.
  • Sigurdardottir FD, Lyngbakken MN, Holmen OL, Dalen H, Hveen K, Rojso H et al. Relative prognostic value of cardiac troponin I and C-reactive...
  • Whelton PK. Epidemiology of hypertension. Lancet 1994; 344: 101-6.
  • de Simone G, Devereux RB, Daniels SR, Meyer RA. Gender differences in left ventricular growth. Hypertension 1995; 26: 979-83.
  • Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85:...
  • Curtis AB, Karki R, Hattoum A, Sharma UC. Arrhythmias in Patients ≥ 80 Years of Age: Pathophysiology, Management, and Outcomes. J Am Coll...
  • North BJ, Sinclair DA. The intersection between aging and cardiovascular disease. Circ Res 2012; 110: 1097-108.
  • Yazdanyar A, Newman AB. The burden of cardiovascular disease in the elderly: Morbidity, mortality, and costs. Clin Geriatr Med 2009; 25: 563-77.
  • Morrow DA, Cannon CP, Jesse RL, Newby K, Ravkilde J, Storrow A et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice...
  • deFilippi CR, de Lemos JA, Christenson RH, Gottdiener J, Kop W, Zhan M et al. Association of serial measures of cardiac troponin T using a...
  • Saunders JT, Nambi V, de Lemos JA, Chambless L, Virani S, Boerwinkle E et al. Cardiac troponin T measured by a highly sensitive assay predicts...
  • Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe E, Cheng S et al. Prognostic utility of novel biomarkers of cardiovascular stress: the...
  • Eggers KM, Venge P, Lindahl B, Lind L. Cardiac troponin I levels measured with a high-sensitive assay increase over time and are strong predictors...
  • Gore MO, Seliger SL, Defilippi CR, Nambi V, Christenson R, Hashim I et al. Age- and sex-dependent upper reference limits for the highsensitivity cardiac...
  • Benjamin EJ, Muntner P, Alonso A, Bittencount M, Callaway C, Carson A et al. Heart Disease and Stroke Statistics-2019 Update: A Report From...
  • Jia X, Sun W, Hoogeveen RC, Nambi V, Matsushita K, Folsom A et al. High-sensitivity troponin I and incident coronary events, stroke, heart failure...
  • Cangemi R, Romiti GF, Campolongo G,Ruscio E, Sciomer S, Gianfrilli D et al. Gender related differences in treatment and response to statins...
  • Scott PE, Unger EF, Jenkins MR, Southworth MR, McDowell TY, Geller R et al. Participation of women in clinical trials supporting FDA approval...
  • Willeit P, Welsh P, Evans JDW, Tschiderer L, Boachie C, Jukema JW et al. High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular...